REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
08/25/2025
Back to search
Official data from USPTO
TOWA PHARMACEUTICAL
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
TOWA PHARMACEUTICAL
ST13
US500000087305763Class
5, 42
Filing
87305763
Registration
6136578
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
71
Latest update
08/26/2025
Classification
Registered
Trademark type
Word
Nice classes
5, 42
Filing date
01/18/2017
Registration date
08/25/2020
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/25/2020
Last transaction
08/26/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
01/01/2017
First use in commerce
01/01/2019
Drawing code
4
Owner type
03
Owner location
Osaka, JP
Examiner
SPARACINO, MARK
Law office
L30
Current location
TMEG LAW OFFICE 102
Holders and representatives
Holders
Towa Pharmaceutical Co., Ltd.
Representatives
Jeffrey H. Handelsman Greenblum & Bernstein, P.L.C.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous systemthe immune systemthe cardio-vascular systemthe metabolic systemthe respiratory systemthe musculo-skeletal systemthe genitourinary system; for the treatment of inflammatory disorders; for use in dermatologyoncologyhematology and in tissue and organ transplantationin ophthalmology and for gastroenterological disorders; Pharmaceutical preparationsa drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals(Based on 44(e)) Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous systemthe immune systemthe cardio-vascular systemthe metabolic systemthe respiratory systemthe musculo-skeletal systemthe genitourinary system; for the treatment of inflammatory disorders; for use in dermatologyoncologyhematology and in tissue and organ transplantationin ophthalmology and for gastroenterological disorders; Pharmaceutical preparationsa drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals
Class 42
Conducting early evaluations in the field of new pharmaceuticals; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development in the pharmaceutical and biotechnology fields; Research on the subject of pharmaceuticals
Publications
History of USPTO decisions and trademark events.
71 publications found
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/20/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/20/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
04/20/2022
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
04/20/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/20/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/20/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/20/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
08/25/2020
AMPB
AMENDMENT/PETITION AFTER APPROVAL FOR PUB ENTERED
07/20/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
07/18/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
07/17/2020
NREV
NOTICE OF REVIVAL - E-MAILED
07/16/2020
PGRR
PETITION GRANTED - RESPONSE RECEIVED
07/16/2020
APET
ASSIGNED TO PETITION STAFF
07/08/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/11/2020
PROA
TEAS PETITION TO REVIVE RECEIVED
05/11/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/04/2020
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
05/04/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/04/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/04/2020
MAB2
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
04/01/2020
ABN2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
04/01/2020
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
09/17/2019
GNFR
FINAL REFUSAL E-MAILED
09/17/2019
CNFR
SU - FINAL REFUSAL - WRITTEN
09/17/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/03/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/03/2019
ALIE
ASSIGNED TO LIE
08/29/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/23/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/24/2019
GNRT
NON-FINAL ACTION E-MAILED
05/24/2019
CNRT
SU - NON-FINAL ACTION - WRITTEN
05/24/2019
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
05/24/2019
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
05/17/2019
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
05/16/2019
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
05/15/2019
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
05/10/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/07/2019
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
05/07/2019
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
05/06/2019
SUPC
STATEMENT OF USE PROCESSING COMPLETE
05/05/2019
EX2G
SOU EXTENSION 2 GRANTED
05/05/2019
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
05/05/2019
NREV
NOTICE OF REVIVAL - E-MAILED
04/24/2019
IUAF
USE AMENDMENT FILED
04/23/2019
EISU
TEAS STATEMENT OF USE RECEIVED
04/23/2019
TPEX
SOU EXTENSION RECEIVED WITH TEAS PETITION
04/23/2019
PETG
PETITION TO REVIVE-GRANTED
04/23/2019
PROA
TEAS PETITION TO REVIVE RECEIVED
04/23/2019
MAB6
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
02/25/2019
ABN6
ABANDONMENT - NO USE STATEMENT FILED
02/25/2019
EXT2
SOU EXTENSION 2 FILED
01/23/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/24/2018
EX1G
SOU EXTENSION 1 GRANTED
07/22/2018
EXT1
SOU EXTENSION 1 FILED
07/22/2018
EEXT
SOU TEAS EXTENSION RECEIVED
07/22/2018
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
01/23/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/28/2017
PUBO
PUBLISHED FOR OPPOSITION
11/28/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/08/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/19/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/17/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/17/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/17/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/18/2017
GNRT
NON-FINAL ACTION E-MAILED
04/18/2017
CNRT
NON-FINAL ACTION WRITTEN
04/18/2017
DOCK
ASSIGNED TO EXAMINER
04/13/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/25/2017
NWAP
NEW APPLICATION ENTERED
01/21/2017
Continuous trademark protection
Get notified about every new filing that threatens TOWA PHARMACEUTICAL or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.